Nuwellis, Inc. (NASDAQ:NUWE) Short Interest Down 83.3% in December

Nuwellis, Inc. (NASDAQ:NUWE) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totaling 8,554 shares, a decrease of 83.3% from the November 30th total of 51,367 shares. Approximately 0.6% of the shares of the stock are short sold. Based on an average daily volume of 55,808 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 55,808 shares, the short-interest ratio is presently 0.2 days. Approximately 0.6% of the shares of the stock are short sold.

Nuwellis Price Performance

NUWE stock traded down $0.02 during trading on Friday, reaching $2.04. The company had a trading volume of 19,725 shares, compared to its average volume of 39,794. Nuwellis has a 52 week low of $2.01 and a 52 week high of $70.14. The business has a 50 day moving average of $2.57 and a 200 day moving average of $5.55. The company has a market cap of $3.39 million, a P/E ratio of -0.02 and a beta of -0.17.

Nuwellis (NASDAQ:NUWE) last posted its quarterly earnings data on Wednesday, November 12th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of ($17.22) by $17.78. Nuwellis had a negative return on equity of 1,367.63% and a negative net margin of 202.83%.The business had revenue of $2.22 million for the quarter, compared to analysts’ expectations of $2.50 million. Research analysts expect that Nuwellis will post -8.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NUWE. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a report on Monday. Wall Street Zen downgraded shares of Nuwellis from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

About Nuwellis

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.